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THE EFFICACY AND SAFETY OF BEDAQUILINE 
IN MULTI-DRUG RESISTANT TUBERCULOSIS 
EDGAR LU 
ABSTRACT 
 Bedaquiline is a medication recently approved by the FDA for the treatment of 
multidrug resistant tuberculosis. Due to its recent nature, there exists little information on 
the efficacy and safety of the drug. A systematic review and meta-analysis was performed 
to collect what data exist on bedaquiline and assess its efficacy and safety relative to 
currently recommended regimens, and some specific medications used in those regimens 
for treating both multidrug resistant and extensively drug-resistant tuberculosis. Nine 
studies were collected from databases and direct journal searches and pooled to make a 
sample size of 950 patients receiving a treatment regimen containing bedaquiline. Of 
these 950 patients on bedaquiline-containing regimens, a high percentage had culture 
conversion at six months (84.13%, 95% CI = 72.53% - 92.98%), treatment cure (71.86%, 
95% CI = 60.94% - 81.60%), and treatment success (70.80%, 95% CI = 61.57% - 
79.24%), and a low percentage discontinued bedaquiline (3.65%, 95% CI = 1.98% - 
5.81%), or died (6.56%, 95% CI = 4.15% - 9.45%), despite a high number of XDR-TB 
and HIV co-infected patients. Adverse events due to bedaquiline (21.39%, 95% CI = 
11.66% - 33.11%), total severe adverse events (26.50%, 95% CI = 6.98% - 52.86%), 
hepatotoxicity (14.37%, 95% CI = 2.56 – 33.47%), and QT prolongation percentages 
(10.37%, 95% CI = 3.19% - 21.01%) were high, but did not lead to bedaquiline 
discontinuation or death. The efficacy and relative safety of bedaquiline make it a viable 
  v 
option versus current alternative medications and, as part of a regimen, it is far more 
successful at treating multidrug-, and extensively drug-, resistant tuberculosis than 
conventional regimens. New treatment regimens only just being put into use, however, 
such as the Bangladesh regimen, still seem to be superior. More research, including 
randomized controlled trials, is required to identify how bedaquiline should be 
incorporated into making multidrug resistant tuberculosis treatment more effective and 
safe. 
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INTRODUCTION 
 
 Tuberculosis (TB) is a major global health problem and one of the top 
contributors to morbidity and mortality each year. Despite a downward trend in the 
overall incidence of TB since 2005, an estimated 10.4 million new cases were reported in 
2015.1 Mortality due to TB has also followed a similar trend, however, TB still claimed 
more lives than HIV/AIDS in 2015 at an estimated 1.4 million.1 In an effort to continue 
promoting these trends, the World Health Organization (WHO) announced in 2014 The 
End TB Strategy which outlines their plans to improve the treatment and prevention of 
TB up to 2035.2 Under this program, WHO aims to reduce the incidence and deaths due 
to TB by 90% and 95%, respectively.2 Multi-drug resistant TB (MDR-TB), however, is a 
major concern because of its potential to mitigate or even reverse the progress made in 
the TB epidemic. MDR-TB is identical to regular tuberculosis with respect to 
transmission and pathogenesis, however, the Mycobacterium tuberculosis exhibits 
resistance to at least isoniazid and rifampin: two antibiotics that are part of the first-line 
of drugs making up the standard treatment for TB.1,3 WHO reported that nearly 4% of TB 
incidences globally, or 480,000 people, were estimated to have MDR-TB in 2015 and 
among those previously treated, this percentage increases to 21%.1,4 Most of these cases 
were centered around Asia and Eastern Europe, with China, India, and Russia accounting 
for nearly half of new cases that year (Figure 1). Of these 480,000 cases, approximately 
9.5% were instances of extensively drug-resistant TB (XDR-TB), cases with MDR and 
resistance to any fluoroquinolone and at least one of the three second-line injectables.1,3 
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The resistance of MDR-TB and XDR-TB to standard treatment significantly hampers 
efforts to treat these cases effectively. Only 52% of MDR-TB and 24% of XDR-TB cases 
were treated successfully in 2013.1 In order to achieve the goals set by The End TB 
Strategy, significant advances must be made in the treatment of MDR-TB and XDR-TB.2 
Figure 1: Estimated incidence of MDR-TB/RR-TB in 2015. New cases of MDR-
TB/RR-TB are primarily centered around Asia and Eastern Europe but occur in Africa as 
well as certain parts of South America. Besides China, India, and Russia, other countries 
of note with high incidence rates include Indonesia, Nigeria, Pakistan, South Africa, and 
Ukraine with an incidence of over 20,000 cases of MDR-TB/RR-TB each. (Copied from 
WHO 2016). 
Complications in the Treatment of MDR-TB and Current Approaches 
 Conventional treatments for MDR-TB, and by extension XDR-TB, place an 
enormous burden on healthcare systems globally. Without the ability to use isoniazid or 
rifampin, therapy is highly toxic, ineffective, expensive, and may require regimens that 
are up to four times as long as drug-susceptible TB (DS-TB).5,6 These disadvantages are 
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largely due to the medications that are used in place of those used for DS-TB.6 WHO 
recommends a combination of at least five drugs in its conventional longer regimen to 
treat MDR-TB (Table 1).6 A typical regimen following these guidelines consists of 
pyrazinamide, a fluoroquinolone from group A, a second-line injectable from group B, 
and two agents chosen from group C.6 In the event that a regimen of this composition 
cannot be made, medications from groups D2 and D3 may be used instead.6 Regimens 
made with these guidelines can either be standardized, where patients receive the same 
treatment, or individualized, where each patient is given a specific combination of 
medications based on the patient’s drug susceptibility testing (DST) to maximize 
effectiveness. Treatments administered under these guidelines have shown moderate 
success in treating MDR-TB, however, medications from groups B,C, and D3 have also 
been shown to have high rates of adverse events (AE) attributed to their use.5–7 Group B 
injectables, an indispensable component of these regimens, caused serious adverse events 
(SAE) in 7.3% of the patients treated.6,7 The usage of some medications, such as 
ethambutol, have also shown little association with overall treatment success and, in the 
case of D3 agents, have been associated more with negative outcomes than with 
treatment success.8,9 Additionally, the cost of these regimens can range from $2000-
20,000 USD per patient, an increase of twenty-fold over what it costs to treat a DS-TB 
patient for the necessary treatment duration of 18-24 months (Figure 2).1 These factors 
may contribute to high rates of patient loss to follow-up seen in MDR-TB cases, where 
13% were lost in one review of 31 TB programs.10 
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Table 1. Medicines recommended for the treatment of RR-TB and MDR-TB (Data 
taken from World Health Organization: WHO Treatment Guidelines for Drug-Resistant 
Tuberculosis) 
Group - Classification Medication Name Abbreviations 
Group A – Fluoroquinolones Levofloxacin 
Moxifloxacin 
Gatifloxacin 
Lfx 
Mfx 
Gfx 
Group B – Second-line Injectable 
Agents 
Amikacin 
Capreomycin 
Kanamycin 
Streptomycin 
Am 
Cm 
Km 
S 
Group C – Other Core Second-
line Agents 
Ethionamide/Prothionamide 
Cycloserine/Terizidone 
Linezolid 
Clofazimine 
Eto/Pto 
Cs/Trd 
Lzd 
Cfz 
Group D1 – Add-on Agents Pyrazinamide 
Ethambutol 
High-dose Isoniazid 
Z 
E 
Hh 
Group D2 – Add-on Agents Bedaquiline 
Delaminid 
Bdq 
Dlm 
Group D3 – Add-on Agents p-Aminosalicylic Acid 
Imipenem-cilastatin 
Meropenem 
Amoxicillin-clavulanate 
Thioacetazone 
PAS 
Ipm 
Mpm 
Amx-Clv 
T 
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Figure 2: Estimated cost per patient treated for MDR-TB in 82 countries, 2015. 
While the cost per patient in some countries with small MDR-TB burdens might be low, 
most with large burdens such as Russia, South Africa, and Kazakhstan are exceedingly 
high. (Copied from WHO 2016). 
 In recent years, there have been multiple advancements in the treatment of MDR-
TB that aim to improve the shortcomings of the conventional regimen. One particularly 
successful endeavor has been a treatment program introduced in Bangladesh known as 
the “Bangladesh regimen.”8 A standardized treatment program consisting of kanamycin, 
gatifloxacin, prothionamide, high-dose isoniazid, clofazimine, pyrazinamide, and 
ethambutol, the Bangladesh regimen achieved success in 88% of patients with a 
treatment duration of only 9-11 months.11 The regimen is now the standard treatment 
recommended by WHO for the treatment of MDR-TB cases not treated before with 
second-line medications.6 
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 While treatment regimens for MDR-TB have improved dramatically, there has 
been very little progress in developing the drugs that are used in them. Until recently, 
most of the medications used to treat MDR-TB were developed decades earlier.12 
Bedaquiline and delaminid, both introduced under group D2, are drugs with novel 
mechanisms of action that have gained approval for conditional use.12,13 Due to their 
relatively new nature, however, there is little information regarding their efficacy and 
safety outside of phase II clinical trials and phase III trials that are still currently 
ongoing.12,13  
Bedaquiline 
 Bedaquiline (Bdq), also known as Sirturo or TMC207, was discovered by Janssen 
Pharmaceutica in 2004 as part of a new class of drugs known as diarylquinolines 
(DARQs).14 DARQs have highly specific 3’ chains and a unique target, making them 
fundamentally different in structure and function compared to other medications such as 
fluoroquinolones (Figure 3).14 DARQs exhibit antimycobacterial properties due to their 
inhibition of the ATP synthase protein in Mycobacterium tuberculosis and do so by 
binding the intramembrane portion of the protein, the F0 unit (Figure 4).15,16 Once bound, 
they mimic the Arg-186 residue of the F0’s a-subunit to interact with the c-subunit’s Glu-
61 residue.15 This prevents protons from exiting the protein and ATP from being 
synthesized.15 Of the DARQs, bedaquiline was evaluated to have the best 
antimycobacterial properties of its class and, in 2012, obtained accelerated approval by 
the FDA specifically for use in MDR-TB patients as an oral treatment.14,17 
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Figure 3 – Structures of a Fluoroquinolone (Levofloxacin, Left) and a 
Diarylquinoline (Bedaquiline, Right) (Copied from Wikimedia Commons and 
Haagsma et al.)16,18 
 
Figure 4 – Structures of ATP Synthase (Left) and C-Subunit (Right) The Glu-61 
residue that is essential to the inhibiting activity of Bedaquiline is highlighted in red. 
(Copied from Haagsma et al.)16 
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Bedaquiline is currently recommended by WHO as an option only when a 
standard regimen cannot be used, and only for adults with MDR-TB.12 Bedaquiline’s use 
in children or pregnant women is not advised due to the lack of evidence in regards to its 
efficacy and safety.12,17 The CDC recommends that the drug should never be used alone 
and should only be used in combination with at least three other TB medications.17 
Bedaquiline is also primarily metabolized via CYP3A4 and has a long half-life of 4-5 
months.17 Thus, drugs that alter the activity of CYP3A4 should be avoided and 
bedaquiline should be considered for discontinuation 4-5 months before other 
medications to mitigate the possibility of acquired resistance.17  
There are several adverse effects associated with the use of bedaquiline. While the 
medication can cause headaches, nausea, chest pain, skin rashes, hemoptysis (the 
coughing up of blood or blood-stained mucus), and arthralgia (joint pain), the primary 
concern with bedaquiline’s use is its cardiotoxicity.17 Bedaquiline can cause drug-
induced QT prolongation, a lengthening of the duration of ventricular depolarization and 
repolarization lasting longer than 500ms or 60ms above the patient’s baseline QT 
interval.12,17,19 An increase in the QTc duration (QT interval corrected for heart rate) can 
dramatically increase a patient’s risk of torsades de pointes (TdP), a type of ventricular 
tachycardia; a QTc interval above 500ms increases this risk by approximately two to 
three fold.19 Torsades de pointes can sometimes resolve on its own but at other times it 
can lead to ventricular fibrillation and ultimately death.19 Patients with MDR-TB may be 
especially susceptible to QT prolongation and TdP because other medications, including 
fluoroquinolones and clofazimine, can also cause QT prolongation and are ubiquitous in 
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MDR-TB regimens.19 Hepatotoxicity is also a concern when taking bedaquiline.17 The 
CDC recommends the monitoring of aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), and bilirubin, and that other hepatotoxic medications be avoided 
during its use.17 
This review seeks to consolidate and analyze the results of multiple studies on 
bedaquiline as part of an adult MDR-TB regimen. The primary objective is to evaluate 
the efficacy and safety of this medication in this context in comparison to currently 
recommended treatment regimens. Secondary objectives include the examination of 
bedaquiline’s potential as a viable replacement for other group D drugs in a regimen and 
as an agent that can further improve upon the Bangladesh regimen’s successes. 
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PUBLISHED STUDIES 
 
 This systematic review was conducted according to PRISMA (preferred reporting 
items for systematic review and meta-analyses) guidelines.20 
Selection Criteria and Search Strategy 
 To obtain adequate data on the safety and efficacy of bedaquiline, studies needed 
to have samples of five or more patients, confirmed sputum cultures, DST, and reports on 
the efficacy and safety of the regimen used. Studies with fewer than 5 patients were 
excluded to minimize selection and reporting biases. Furthermore, studies had to follow 
WHO recommendations for the administration of bedaquiline on aspects including 
dosage and duration of treatment as well as WHO outcome definitions.21 PubMed, Web 
of Science, and EMBASE were used to search for studies that fit these criteria published 
between January 2004 and September 2017. The starting date was chosen because of 
bedaquiline’s discovery in 2004. To supplement these results, searches were also made in 
the European Respiratory Journal for additional studies on bedaquiline. Combinations of 
the terms “multi-drug resistant tuberculosis,” “bedaquiline,” “sirturo,” “TMC207,” 
“efficacy,” and “toxicity” and their synonyms were all used to compose these queries. 
“Sirturo” and “TMC207” were included as search terms because “Sirturo” is the 
marketed brand name for bedaquiline by Janssen Pharmaceutica and “TMC207” was the 
drug’s name when it was still in development. Search results were limited to English 
articles conducted with human participants. 
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Study Quality Assessment 
 The McMaster critical review for quantitative studies was used to assess all 
studies.22 
Data Collection Process 
 A form was created to collect the data from the studies included for analysis. 
Basic study information was collected and included first author name, year of 
publication, country of study, study design, and the presence of any control groups. 
Efficacy data included the number of patients on Bdq, dosage of Bdq used, duration of 
Bdq treatment, additional resistance to medications based on DST, number of XDR-TB 
cases, presence of HIV coinfection, and culture conversion status at the end of Bdq 
administration. HIV coinfection was included as an efficacy variable because it reduces 
the immune system’s ability to handle a TB infection which can negatively impact 
treatment outcome. Treatment outcomes were taken from studies that gave them or were 
assigned if sufficient information was given. Patients were labelled as cured if their 
sputum cultures were negative for the past month and on at least one previous occasion; 
patients who finished treatment but did not have negative cultures for at least a month 
were labelled as having completed treatment. Patients who did not complete their 
treatment, were lost to follow-up, or died were classified as failures. For safety, the 
number of patients who suffered from drug-induced QT prolongation and who died was 
extracted. If possible, the number of patients who experienced any adverse events, along 
with any information regarding the severity of those events according to the Division of 
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AIDS Table for Severity of Adverse Events, and hepatotoxicity data was recorded.23 Any 
grade 3 AEs or above were classified as severe adverse events (SAEs). QT prolongation 
was defined as a QT interval above 500ms or 60ms over the baseline. Only QT intervals 
corrected for heart rate using the Fridericia formula were accepted for analysis; QT 
intervals corrected with Bazzet’s formula were excluded because of the formula’s 
tendency to overestimate the number of patients with QT prolongation.24 
Statistical Analysis 
 Statistical analysis was conducted using SPSS Statistics (Version 25, IBM Corp, 
Armonk, NY, USA), MedCalc (Version 17.9.7, MedCalc Software, Ostend, Belgium), 
StatsDirect (Version 3.1.11, StatsDirect Ltd, Cheshire, UK), and R (Version 3.42, The R 
Foundation For Statistical Computing, Auckland, New Zealand). Both individual study 
and pooled population results were analyzed using proportion meta-analysis and a 95% 
confidence interval (CI). A random effects model was adopted over a fixed effects model 
for calculated proportions. The I2 statistic and Quoran (Q) test were used to assess 
heterogeneity between studies. For all calculations, statistical significance was set to p < 
0.05. For certain aspects of the pooled population analysis, approximations of the mean 
and/or standard deviation were generated when data was presented as medians in source 
studies.25 For proportions with high heterogeneity, meta-regression was performed. The 
moderating variables tested were pre-XDR TB-fq resistance, XDR-TB, and HIV 
coinfection. The use of clofazimine was also included as a covariate for the meta-
regression of QT prolongation because of its potential to also cause QT prolongation. 
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Publication bias was evaluated by funnel plot observation, as well as Egger’s and Begg’s 
tests. 
Risk of Bias 
 This review contains results from interim cohort analyses where patients have 
finished Bdq but may still be on a background regimen, a standard course of treatment 
used in conjunction with and following Bdq administration, as well as results from 
studies where treatment with both Bdq and the background regimen has concluded. 
Culture conversion status at six months, when Bdq treatment is supposed to end, was 
used as the primary measure of efficacy across these studies. At this timepoint, culture 
conversion is a strong predictor of treatment success, however, interim analyses are more 
likely to be published when results are positive.26,27 Thus, results may be skewed to be 
more positive than they actually may be. 
Comparison Studies 
 Three studies were selected to act as comparisons for the efficacy and safety of 
Bdq. The first study was an individual patient data meta-analysis of 9,153 patients 
performed by Ahuja et al.9 The second study was a meta-analysis performed by Bastos et 
al. and was used to provide supplemental efficacy and safety information.7 Both informed 
WHO’s latest guidelines for treatment with their conclusions.6,7,9 The third study, 
performed by Khan et al., was a meta-analysis of TB programs utilizing the shorter 
Bangladesh regimen that is one of the current methods used to overcome the limitations 
of MDR-TB treatment.8 
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RESULTS 
 
 
Study Identification and Selection 
 A total of 973 records were identified in total: 970 obtained from database 
searches and an additional 3 added from the European Respiratory Journal (Figure 5). 
The elimination of duplicate articles removed 478 records from consideration, leaving 
495 articles to be reviewed by titles and abstracts. From this pool, an additional 470 
records were disqualified and 25 were selected for full text review. Of these articles, 16 
were ineligible for various reasons such as the lack of DST reporting, and insufficient 
treatment duration, and the remaining 9 records were included in the following analysis. 
All included studies met the quality assessment guidelines set by the McMaster critical 
review form.  
The studies included were largely composed of case series studies (n=4, 44%) 
(Table 2). Cohort studies, both prospective and retrospective, and phase 2 clinical trials 
made up the remainder (n=3, 33% and n=2, 22%). All studies were published in the past 
3 years (2014-2017) and included patients from 27 countries on 5 continents. European 
countries were the most represented among these studies (n=15). The rest of the studies 
were conducted in Asia (n=6), South America (n=4), Africa (n=1), and Australia (n=1); 
there were no studies done in North America. All studies, aside from a phase 2 clinical 
trial by Diacon et al., included patients on an individualized background regimen in 
conjunction with Bdq.28 Besides Olaru et al., all studies also provided information about 
the composition of their background regimens.29 
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Figure 5 – Study Selection Process 
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Study Population 
 In this analysis, a combined total of 950 patients with MDR-TB was treated with  
a bedaquiline-containing regimen between 2007 and 2016. The mean age of this 
population was 36.2 years and there were more male (n=606, 64%) than female (n=344, 
36%) patients (Table 3). A large percentage of patients had received prior TB treatment 
before being placed on a Bdq-containing regimen (82.6%). Additional DST results, 
where available, indicated that 38.1% of cases were MDR-TB without additional drug 
resistance. A portion of the population carried pre-XDR strains of TB: TB strains that 
were resistant to more medications than standard MDR-TB strains but not to the extent of 
being classified as XDR-TB. 20.1% of MDR-TB patients exhibited additional resistance 
to fluoroquinolones and 9.6% were resistant to second-line injectables. XDR-TB was 
present in 35.8% of patients. 17.6% of the patients were coinfected with HIV.  
 All patients were treated according to WHO’s interim guidelines for Bdq 
administration.12,17 Patients took 400 mg of Bdq daily for the first two weeks followed by 
200 mg three times a week for the following twenty two weeks, totaling a duration of 
roughly six months. Treatment with Bdq was used in conjunction with a background 
regimen that included fluoroquinolones (69.9%), ethionamide (66.8%), pyrazinamide 
(65.7%), aminoglycosides (61.3%), cycloserine (50.5%), clofazimine (38.3%), p-
aminosalicylic acid (59.0%), and ethambutol (50.0%). 
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Study 
No. 
Reference Year of 
Publication 
Country of Study Study Design Control 
Group 
Individualized 
Regimen 
1 Olaru et 
al.29 
2017 Germany Retrospective Case Series No Yes 
2 Pym et al.30 2015 China, South Korea, the 
Philippines, Thailand, 
Estonia, Latvia, Russia, 
Turkey, Ukraine, Peru, 
South Africa 
Prospective Phase II 
Clinical Trial 
No Yes 
3 Guglielmetti 
et al.31 
2014 France Retrospective Case Cohort 
Study 
No Yes 
4 Udwadia et 
al.32 
2017 India Prospective Case Series No Yes 
5 Borisov et 
al.33 
2017 Argentina, Australia, 
Belarus, Belgium, Greece, 
India, Italy, the Netherlands, 
Peru, Portugal, Russia, 
South Africa, Spain, 
Sweden, United Kingdom 
Retrospective Case Series No Yes 
6 Udwadia et 
al.34 
2014 India Prospective Case Series No Yes 
7 Guglielmetti 
et al. 35 
2017 France Retrospective Cohort 
Study 
No Yes 
8 Diacon et al. 
28 
2014 Brazil. India, Latvia, Peru, 
the Philippines, Russia, 
South Africa, Thailand 
Prospective Phase II 
Clinical Trial 
Yes No 
9 Ndjeka et 
al.36 
2015 South Africa Prospective Cohort Study No Yes 
Table 2 – Characteristics of Included Studies 
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Variables Number (n/N (%)) 
Demographic Characteristics  
Male 606/950 (64%) 
Mean Age (Years) 36.2 
Prior TB Treatment 655/793 (82.6%)A 
Drug Resistance  
MDR-TB – Fq and Injectable Susceptible 199/522 (38.1%)B 
Pre-XDR TB – Fq Resistant 188/936 (20.1%) 
Pre-XDR TB – Injectable Resistant  50/522 (9.6%)B 
XDR-TB 340/950 (35.8%) 
Background Regimen  
Fluoroquinolones 626/895 (69.9%) 
Ethionamide/Prothionamide 251/376 (66.8%) 
Pyrazinamide 247/376 (65.7%) 
Aminoglycosides (Injectables) 493/804 (61.3%) 
Cycloserine/Terizidone 190/376 (50.5%) 
Clofazamine 343/895 (38.3%) 
p-Aminosalicylic Acid 183/310 (59.0%)C 
Ethambutol 188/376 (50.0%) 
HIV Coinfection 166/942 (17.6%) 
Table 3 – Demographic Characteristics of the 950 Patients with MDR-TB/XDR-TB 
A Diacon et al. and Ndjeka et al. did not report how many of their patients had received 
prior TB treatment. B Numbers could not be generated for Borisov et al. due to different 
methods of reporting DST. C Diacon et al. reported the usage of p-aminosalicylic acid 
under “other drugs” which included amoxicillin-clavulanate and streptomycin and so 
could not be included. 
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Efficacy 
Of the 950 patients treated with Bdq across all studies, culture conversion at the 
end of six months was available for 654 patients. 62 patients had negative sputum 
cultures at the start of treatment while 8 were not able to secure Bdq within one month of  
starting treatment. A reason was not given for why the latter 8 patients were not included 
for analysis and for the lack of culture conversion status in 213 other patients. The pooled 
population of all studies reported a combined sputum culture conversion percentage of 
84.13% (95% CI = 72.53% - 92.98%) (Figure 6). The Quoran (Q) and I2 tests showed 
high heterogeneity across studies with a Q value of 88.02 (p < 0.0001) and  
Figure 6 – Forest Plot of Culture Conversion for Individual Studies and the Pooled 
Population (Random Effects) 
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an I2 percentage of 90.91% (95% CI = 85.01% - 94.49%). Two studies, Olaru et al. and 
Udwadia et al. with a total of 25 patients, achieved 100% sputum culture conversion and 
all studies reported conversion in at least 50% of their patients. In comparison, only 62% 
of patients on conventional treatment converted by six months according to Bastos et al.: 
a statistically significant difference (p < 0.0001). 
 Treatment outcome data was available for 807 patients across 8 studies. Of these 
8 studies, only 3 studies with 627 patients had complete outcome data, from patients who 
completed their full course of treatment. The remaining 5 were interim analyses in which 
all patients completed Bdq but most had not yet finished their background regimen. The  
   
Figure 7 – Forest Plot of Patient Cure for Individual Studies and the Pooled 
Population (Random Effects) – Olaru et al. did not report patient treatment outcomes. 
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Figure 8 – Forest Plot of Treatment Success, Individual and Pooled Populations 
(Random Effects)  
pooled population of 807 patients had a cure percentage of 71.86% (95% CI = 60.94% - 
81.60%) (Figure 7). Heterogeneity was also high across studies with a Q value of 55.56 
(p < 0.0001) and an I2 percentage of 87.40% (95% CI = 77.37% - 92.98%). Only one 
study, Udwadia et al., reported 100% cure (95% CI = 47.82% - 100.00%) for 5 patients. 
Another study, Udwadia et al., reported a cure proportion of less than 50%. Treatment 
success, a combined count of cured patients and patients with completed treatment, 
showed a similar percentage of 70.80% (95% CI = 61.57% - 79.24%) for the 627 patients 
where this data was available, as well as a similarly high I2 percentage of 78.58% (95% 
CI = 31.23% - 93.33%) (Figure 8). Bastos et al. reported 58% of patients in its study with 
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successful treatment, a statistically significant difference compared to both measures (p < 
0.0001). Ahuja et al. reported similar treatment success rates for patients on ethambutol 
and any D3 medication at 52.64% and 53.92% respectively with overall success at 54%, 
all statistically significant (p < 0.0001). Khan et al. observed 83.0% of their patients with 
success, also statistically significant (p < 0.0001). 
Adverse Events and Safety 
 The number of adverse events related to Bdq use was provided in 4 studies, a total 
of 686 patients. The pooled percentage of patients with Bdq-related AEs was 21.39% 
(95% CI = 11.66% - 33.11%) (Figure 9). Heterogeneity was high according to a Q value 
of 19.19 (p < 0.003) and an I2 percentage of 84.36% (95% CI = 60.81% - 93.76%). One 
study, Udwadia et al., reported no AEs attributable to Bdq use in the 5 patients in the 
study. None of the studies reported AEs due to Bdq in more than 40% of their patients.  
 Bdq discontinuation numbers were reported by 8 studies, a total of 854 patients. 
Bdq discontinuation was seen in only 3.65% of patients (95% CI = 1.98% - 5.81%) with 
a low reported heterogeneity of 32.88% (95% CI = 0.00% - 70.22%) in the I2 calculation 
and a Q score of 10.43 (p = 0.17) (Figure 10). All studies observed less than 10% of their 
subjects discontinuing Bdq treatment and 3 studies reported that none of their patients 
discontinued treatment. In contrast, in the study by Bastos et al., 6 patients discontinued 
ethambutol (1.12%) and 207 patients discontinued any group D3 medications (18.89%); 
both statistically significant (p = 0.0045 and p < 0.0001). 
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Figure 9 – Forest Plot of Adverse Effects due to Bedaquiline Usage in Individual 
and Pooled Populations (Random Effects) – Data was not available for Olaru et al., 
Guglielmetti, et al., Guglielmetti et al., Diacon et al., and Ndjeka et al. 
The proportion of patients who suffered from at least one SAE in the pooled 
population of 468 was 26.50% (95% CI = 6.98% - 52.86%) (Figure 11). The Q score was 
122.64 (p < 0.0001) and the I2 percentage was 96.74% (95% CI = 94.54% – 98.05%) 
indicating high heterogeneity. Udwadia et al. reported no SAEs throughout its TB 
regimen while Guglielmetti et al. had over 75% of its patients experiencing at least one 
SAE. Bastos et al. reported 6 patients with SAEs due to ethambutol (1.12%), a 
statistically significant difference (p = 0.0007) when compared to Bdq. Khan et al. 
observed a statistically significant 18.1% of their patients experiencing SAEs. 
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Figure 10 – Forest Plot of Bedaquiline Discontinuation in Individual and Pooled 
Populations (Random Effects) – Diacon et al. did not provide treatment discontinuation 
data specific to bedaquiline usage. 
The pooled proportion of hepatotoxicity was 14.37% (95% CI = 2.56 – 33.47%) 
out of 371 patients from 4 studies (Figure 12). A portion of patients from Guglielmetti et 
al. were excluded because they were administered Bdq for a longer period than 
recommended.35 Heterogeneity was high across studies at 92.77% (95% CI = 84.71 – 
96.57%). Ndjeka et al. reported no events of hepatotoxicity in its 91 patients while 
Guglielmetti et al. reported hepatotoxicity in half of their 12 patients. 
QT interval data corrected with Fridericia’s formula were available for 7 studies 
and 687 patients. QT prolongation was experienced by 10.37% (95% CI = 3.19% - 
21.01%) of patients (Figure 13). The Q value was 70.12 (p < 0.0001) and the I2 
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Figure 11 – Forest Plot of Severe Adverse Events in Individual and Pooled 
Populations (Random Effects) – Olaru et al., Guglielmetti et al., Borisov et al., and 
Udwadia et al. did not report this data or provided data from which AE grades could not 
be extrapolated.  
percentage was 91.44% (95% CI = 84.94% – 95.14%), indicating high heterogeneity. The 
number of patients in each study experiencing QT prolongation did not exceed 33%. 
Udwadia et al. reported no QT prolongation among its patients and none of the 5 study 
subjects exceeded a QT interval of 420ms during Bdq treatment. 
 Of the 950 patients across all studies, 6.56% (95% CI = 4.15% - 9.45%) died 
during treatment or follow-up (Figure 14). There was low heterogeneity observed from a 
Q score of 15.50 (p = 0.05) and an I2 percentage of 40.9% (95% CI = 0.00% - 71.3%). 
Three studies, Olaru et al., Udwadia et al., and Udwadia et al., reported no deaths among 
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Figure 12 – Forest Plot of Hepatotoxicity in Individual and Pooled Populations 
(Random Effects) – Olaru et al., Udwadia et al., Borisov et al, Udwadia et al., and 
Diacon et al. did not provide hepatotoxicity information. 
their samples. There were also two studies in which more than 10% of the study subjects 
died: Guglielmetti et al., and Diacon et al. In every study where deaths occurred and a 
specific cause of death was reported, most deaths were TB related. Both QT prolongation 
and torsades de pointes were ruled out as causes of death in all cases, suggesting that 
treatment with Bdq was not the cause of death. In comparison studies, Ahuja et al. 
reported 15.21% of patients died (p < 0.0001). Bastos et al. and Khan et al. reported 12% 
and 6.41% of their patients died, respectively (p <0.0001 and p = 0.8992). 
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Figure 13 – Forest Plot of QT Prolongation in Individual and Pooled Populations 
(Random Effects) – Olaru et al. and Guglielmetti et al. provided readings in QTcB 
instead of QTcF and were excluded. 
Heterogeneity and Meta-Regression 
 Meta-regression analyses were performed to explain the significant heterogeneity 
observed in nearly all measures of Bdq’s efficacy and safety. XDR-TB and pre-XDR TB-
FqR had statistically significant impacts on treatment success with R2 values of 100.00% 
and 94.01%, respectively (Table 4). XDR-TB was statistically significant for Bdq related 
AEs. HIV coinfection was statistically significant for hepatotoxicity (R2 = 64.65%). 
XDR-TB, pre-XDR TB-FqR, and clofazimine had statistically significant influences on 
QT prolongation (56.32%, 44.11%, 92.18%). For the occurrence of culture conversion at 
six months, treatment cure, and SAEs, none of the covariates could explain the high 
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Figure 14 – Forest Plot of Deaths in Individual and Pooled Populations (Random 
Effects) 
 Covariates (R2% (p-value)) 
Study 
Proportions 
Pre-XDR TB-Fq 
Resistance 
XDR-TB HIV 
Coinfection 
Clofazimine 
Culture 
Conversion 
0.00% 
(p = 0.5926) 
7.02% 
(p = 
0.1624) 
5.39% 
(p = 0.1709) 
- 
Treatment 
Cure 
9.23% 
(p = .3059) 
0.00% 
(p = 
0.6959) 
0.00% 
(p = 0.3049) 
- 
Treatment 
Success 
94.01% 
(p = 0.0120) 
100.00% 
(p = 
0.0026) 
0.00% 
(p = 0.8381) 
- 
AEs due to 
Bdq 
21.98% 
(p = 0.2179) 
100.00% 
(p < 
0.0001) 
0.23% 
(p = 0.3583) 
- 
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G3/G4 AEs 31.83% 
(p = 0.0885) 
0.00% 
(p = 
0.6939) 
36.93% 
(p = 0.1209) 
- 
Hepatotoxicity 0.00% 
(p = 0.2746) 
0.00% 
(p = 
0.5237) 
64.65% 
(p = 0.0319) 
- 
QT 
Prolongation 
44.11% 
(p = 0.0368) 
56.32%  
(p = 
0.0122) 
0.00% 
(p = 0.2946) 
92.18% 
(p < 0.0001) 
Table 4 – Heterogeneity Accountable through Covariates 
heterogeneity observed. 
Publication Bias 
 Funnel plots were generated to assess the presence of publication bias (Figure 15). 
Plots for death and Bdq discontinuation did not show any signs of asymmetry. Plots for 
culture conversion, treatment cure, and QT prolongation showed some asymmetry 
indicating the possibility of publication bias. For Bdq related AEs, SAEs, and 
hepatoxicity, asymmetry could not be assessed because of the low number of studies 
included. Begg’s rank correlation and Egger’s regression tests were run to provide a more 
objective view of all proportions and none showed any statistically significant publication 
bias (Table 5). 
 Bias Indicators (P-Value) 
Study Proportions Begg’s Rank Correlation Egger’s Linear 
Regression 
Culture Conversion p = 0.1802 p = 0.3058 
Treatment Cure p = 0.2751 p = 0.6695 
AEs due to Bdq p = 0.75 p = 0.8608 
G3/G4 AE p = 0.2333 p = 0.156 
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Hepatotoxicity p = 0.75 p = 0.1187 
QT Prolongation p = 0.3813 p = 0.0828 
Death p = 0.7614 p = 0.471 
Table 5 – Publication Bias Indicator Values – Values could not be calculated for 
treatment success. 
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Figure 15 – Funnel Plots of Calculated Proportions – Culture conversion, treatment 
cure, AEs due to Bdq, Bdq discontinuation due to AEs, G3/G4 AEs, hepatotoxicity, QT 
prolongation, and deaths from left to right. A funnel plot could not be generated for 
treatment success due to inadequate strata.  
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DISCUSSION 
 
 The recent nature of bedaquiline’s discovery and subsequent use in treating 
MDR-TB have made it both a prime topic for investigation and a challenge to gather 
meaningful data for analysis. As of this systematic review and meta-analysis, nearly all 
published studies were case series or cohort studies without control groups. Only one 
randomized controlled trial performed by Diacon et al. with a sample size of 66 was 
identified. Without many publicized randomized controlled trials, proportion meta-
analyses were used to assess these studies. Using the large pooled sample size of 950 
patients, however, it was possible to make robust observations regarding the efficacy and 
safety of bedaquiline in MDR-TB regimens. 
Efficacy 
 Pooled proportions measuring bedaquiline’s efficacy showed marked 
improvement over conventional treatment. With respect to culture conversion at six 
months, treatment cure, and treatment success, there were statistically significant 
differences (p < 0.0001) between patients on Bdq and patients on conventional treatment 
in studies by Ahuja et al. and Bastos et al. that greatly favored the usage of Bdq. The 
treatment improvements in the Bdq group over the conventionally treated groups were 
achieved in spite of a significantly higher percentage of XDR-TB patients, who have 
historically had much lower rates of culture conversion (19.60%), and treatment success 
(26.44%) than MDR-TB patients.7 
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 The effectiveness of bedaquiline-containing regimens was also apparent when 
compared to other medications in the D class. Bdq-containing regimens showed 
statistically significant differences over regimens using ethambutol and other D3 
medications (p < 0.0001) in the study by Ahuja et al. in treatment success. While the 
improvement seen may not have been entirely due to Bdq because of its use with a 
combination of drugs that may have also included ethambutol and/or D3 drugs, its role in 
improving treatment success is supported by its inclusion into a regimen usually upon 
previous treatment failure. 
 While bedaquiline-containing regimens were effective compared to conventional 
treatments, the Bangladesh regimen-based treatments reviewed by Khan et al. were still 
more effective than both conventional regimens with or without Bdq in terms of 
treatment success with a statistically significant difference (p < 0.05). Bastos et al. 
indicated in their review that individualized treatments were generally more effective 
than standardized ones in conventional regimens. However, despite the individualized 
Bdq regimens used in most studies, Khan et al.’s study utilizing a standardized regimen 
reported a greater percentage of successfully treated patients. This difference could 
possibly be explained by the exclusion of all XDR-TB patients from the results or the low 
percentage of patients with HIV coinfection in Khan et al.’s review, however, the 
magnitude of the effects produced by these covariates remains unclear. Thus, cautious 
interpretation of this result is advised. 
Overall, bedaquiline-containing regimens seem to be extremely effective in the 
treatment of MDR-TB. Over 70% of patients receiving regimens including Bdq achieved 
  
34 
 
culture conversion at six months, an early indication of treatment success. Moreover, 
similar proportions in the pooled treatment cure and treatment success of patients implied 
that culture conversion was generally maintained throughout the regimen without much 
relapse occurring: a rare occurrence in MDR-TB treatment.7,37 It is clear that Bdq 
regimens are more effective than conventional ones and should be considered over other 
group D medications in terms of efficacy, however, whether a Bdq regimen is more 
effective than the Bangladesh regimen remains to be seen. 
Adverse Events and Safety  
Bedaquiline, despite its high rates of favorable outcomes in treatment, carries 
significant risk like all other second-line medications for MDR-TB. In this review, Bdq-
related adverse events were quite common, occurring in just over a fifth of patients. 
Although most of these events did not warrant the discontinuation of Bdq, the occurrence 
of severe adverse events should not be overlooked. Severe adverse events that could be 
attributed to Bdq included QT prolongation and hepatotoxicity; over 10% of patients 
experienced these severe adverse events over the course of their treatment. The number 
of patients with QT prolongation may be confounded with the administration of 
clofazimine, a drug that also causes QT prolongation and was shown have a statistically 
significant effect in this review. Despite the non-insignificant rates of severe adverse 
events, however, death was not very prevalent among Bdq regimen cases across all 
studies. Moreover, none of the deaths that occurred were attributed to the usage of Bdq. 
Comparatively, death proportions were higher in studies by both Ahuja et al. and Bastos 
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et al. and were statistically significant (p < 0.001). Again, these percentages were 
achieved in spite of the high number of XDR-TB cases among the study subjects. 
Bedaquiline’s measurements of safety indicated that it was neither the least, nor 
the most, safe when compared to other group D medications. Less than 5% of all patients 
discontinued Bdq, implying Bdq was generally well tolerated. Bastos et al. reported a 
much higher rate of discontinuation from group D3 medications where nearly a fifth of 
all patients had to discontinue, which was statistically significant (p < 0.0001). For 
ethambutol, however, Bastos et al. reported only 1.12% of patients discontinued the drug 
due to adverse events (p < 0.0001): an expected result because of ethambutol’s use as a 
first-line medication for DS-TB.  
Khan et al. reported a similar percentage of discontinuation compared to Bdq 
containing regimens whose difference was not significant (p = 0.8992). 
Strengths and Limitations 
 The primary strength of this study was its large study sample. As noted above, the 
size of the sample allowed robust observations to be made about bedaquiline-containing 
regimens. This sample size was achieved, however, through inclusion of non-randomized 
case series and cohort studies which puts the review at risk of reporting and selection bias 
and necessitated the use of proportions meta-analysis. Moreover, although the sample 
size was large, the number of studies was not. One study, Borisov et al., made up nearly 
half of the pooled sample size.  
 One of the largest limitations of this review has been the incomplete or 
inconsistent reporting of data in the included studies. Of the 9 included studies, a large 
  
36 
 
portion were interim analyses where treatment had not been completed. As a result, 
treatment outcomes, including treatment success, could not be calculated for most 
studies. Only a third of the studies reported hepatotoxicity information and half did not 
report severe adverse events or Bdq-related adverse events. DST and resistance patterns, 
although present and reported by every included study, were not reported in a way that 
allowed them to be pooled. Borisov et al., for example, reported the number of XDR-TB 
patients and Fq resistant pre-XDR patients but reported the number of injectable resistant 
pre-XDR patients by their individual medications.  
Another major limitation in the study was the high heterogeneity present in many 
of the calculated proportions. Although the usage of a random effects model somewhat 
mitigated this, the small number of included studies made assessing sources of 
heterogeneity extremely difficult because conclusive results could not be drawn from 
meta-regression. The further reduction in studies for proportions with incomplete reports 
made meta-regression even more unreliable for explaining observed heterogeneity. 
Conclusions 
 The studies included in this review have shown bedaquiline to be an extremely 
effective treatment for MDR-TB. The rapid culture conversion, consistency from 
conversion to successful treatment outcome, and high rates of both, are remarkable 
improvements over conventional treatment efficacy and medications such as ethambutol 
and D3 drugs. The lower proportions of patient deaths compared to conventional 
treatments and lower rates of discontinuation compared to D3 medications are also highly 
desirable. Ethambutol, while less effective than bedaquiline, should still be used when it 
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can be of benefit per WHO recommendations due to its relative safety. These aspects 
make bedaquiline a viable, and possibly the preferred choice, when prescribing a regimen 
for treating patients with MDR-TB who are not predisposed to QT prolongation or liver 
problems. 
 While bedaquiline-containing regimens have distinct advantages over 
conventional treatments, this is not the case with the Bangladesh regimen. The 
Bangladesh regimen is superior in both efficacy and safety because studies reviewed by 
Khan et al. have shown a greater proportion of patients with successful treatment and a 
lower incidence of severe adverse events with a similar amount of deaths. The inclusion 
of bedaquiline, however, may make the regimen more effective and possibly even 
shorter, a possibility currently being explored by the STREAM trials.38 
 Publications reporting studies on the efficacy and safety of bedaquiline for 
treatment of MDR-TB have indicated a promising start, however, more studies are 
needed as its use increases. Randomized control trials need to be carried out, in addition 
to the standardization of DST, adverse event, and treatment outcome reporting. These 
efforts will help to identify how MDR-TB treatments can be made more effective and 
safe.  
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